Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated is a commercial-stage biopharmaceutical company dedicated to the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders. The company's core mission is to treat serious diseases by modulating the effects of the hormone cortisol, addressing conditions with high unmet medical needs. Headquartered in Redwood City, California, Corcept focuses on pioneering treatments within the field of cortisol modulation.

Corcept's product portfolio includes Korlym (mifepristone), the first FDA-approved oral medication for controlling hyperglycemia secondary to hypercortisolism (Cushing's syndrome) in adult patients. Expanding its therapeutic reach, the company recently received FDA approval in March 2026 for Lifyorli (relacorilant) for the treatment of patients with platinum-resistant ovarian cancer. Corcept also maintains a robust pipeline of selective cortisol modulators, with candidates like dazucorilant in clinical trials for Amyotrophic Lateral Sclerosis (ALS) and miricorilant for metabolic dysfunction-associated steatohepatitis (MASH).

Recent notable developments include the FDA approval of Lifyorli, marking a significant step in the company's oncology program. Furthermore, positive two-year overall survival data from the Phase 2 DAZALS study for dazucorilant in ALS patients has been reported, with a Phase 3 trial anticipated to commence later in 2026. Despite a recent Complete Response Letter from the FDA regarding relacorilant for Cushing's syndrome, Corcept remains engaged with regulators for its approval. Led by CEO Joseph K. Belanoff, MD, Corcept has increased its 2026 revenue guidance to $950 – $1,050 million and expects to return to profitability in the second quarter of 2026, signaling its transition from a single-product entity to a multi-product player in rare diseases and oncology.

Latest updates

Corcept's Lifyorli Launch Drives Revenue Growth, Masks Rising Expenses

Event summary

  • Corcept Therapeutics reported Q1 2026 revenue of $164.9 million, a 3.4% increase year-over-year.
  • Operating expenses rose significantly to $214.5 million in Q1 2026, compared to $153.8 million in Q1 2025, driven by Lifyorli launch preparation and Cushing’s syndrome growth initiatives.
  • The company expects to return to profitability in Q2 2026 following a net loss per share of $0.30 in Q1 2026.
  • Lifyorli, approved for platinum-resistant ovarian cancer, was added to NCCN Guidelines in April 2026, leading to vigorous uptake.
  • Corcept increased its full-year 2026 revenue guidance to $950 - $1,050 million.

The big picture

Corcept's rapid revenue growth is largely attributable to the successful FDA approval and subsequent NCCN inclusion of Lifyorli. However, the company's significant increase in operating expenses, driven by launch preparations and ongoing development programs, is masking a loss in the short term. The company's ability to manage these expenses and demonstrate continued clinical success will be crucial for long-term value creation.

What we're watching

Expense Management
The substantial increase in operating expenses warrants close monitoring to ensure profitability targets are met as Lifyorli sales ramp up and other development programs advance.
Clinical Trial Data
The upcoming results from the BELLA and MONARCH trials will be critical in determining the long-term commercial potential of Lifyorli and miricorilant, respectively.
Regulatory Landscape
The FDA’s path forward for relacorilant in Cushing’s syndrome remains uncertain, and the outcome of this review will significantly impact Corcept’s future revenue stream.

Corcept's ALS Candidate Shows Survival Benefit, Misses Primary Endpoint

Event summary

  • Corcept's Phase 2 DAZALS study of dazucorilant in ALS patients randomized 249 patients to receive 150mg, 300mg of dazucorilant, or placebo for 24 weeks, with extension to 300mg for all.
  • While the study did not meet its primary endpoint (ALSFRS-R score improvement), patients receiving 300mg of dazucorilant daily showed improved overall survival.
  • Two-year data reveal an 87% reduction in the risk of death (HR: 0.13, p<0.0001) for patients on 300mg dazucorilant compared to placebo.
  • Corcept plans to initiate a pivotal Phase 3 study later in 2026, preceded by a dose titration study to improve gastrointestinal tolerability.

The big picture

ALS treatment remains a significant unmet medical need, with limited therapeutic options. While the failure to meet the primary endpoint is a setback, the robust survival benefit observed with dazucorilant represents a potentially significant advancement, particularly given the disease's aggressive progression and limited life expectancy. Corcept's focus on cortisol modulation represents a novel approach to ALS, potentially opening new avenues for therapeutic intervention beyond existing symptomatic treatments.

What we're watching

Regulatory Pathway
The FDA's acceptance of the survival data as sufficient for accelerated approval will hinge on the perceived clinical significance of the benefit versus the lack of primary endpoint achievement, potentially influencing the design of the Phase 3 trial.
Phase 3 Design
The design of the Phase 3 trial will be critical; Corcept's choice of endpoints and patient selection criteria will need to balance the need for statistical significance with clinical relevance, given the existing survival benefit.
Commercialization
The success of Corcept's commercialization efforts will depend on demonstrating a clear value proposition to physicians and patients, particularly given the high cost of ALS therapies and the relatively short life expectancy of patients.

Corcept to Detail Q1 Results Amidst Oncology Expansion

Event summary

  • Corcept Therapeutics will release its first quarter 2026 financial results on April 30, 2026.
  • The company will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on April 30, 2026.
  • Corcept introduced Korlym® in 2012 and Lifyorli™ in 2026, the latter approved for platinum-resistant ovarian cancer.
  • Corcept has over 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists.

The big picture

Corcept’s strategic shift towards oncology, exemplified by the Lifyorli™ approval, represents a move to address a larger market with potentially higher revenue generation. The company’s focus on cortisol modulation remains a niche area, but the success of Lifyorli™ demonstrates the potential for targeted therapies in oncology. The company’s long-term success hinges on expanding its pipeline and demonstrating the versatility of its cortisol modulation platform.

What we're watching

Commercial Traction
The success of Lifyorli™ will be a key indicator of Corcept’s ability to expand beyond Cushing’s syndrome, and the Q1 results will reveal early adoption rates and market penetration.
Pipeline Progress
The company’s progress in advanced clinical trials for ALS and liver disease will be scrutinized, as these represent potential future revenue streams and diversification beyond oncology.
Regulatory Risk
Given Corcept’s reliance on FDA approvals, any changes to regulatory pathways or increased scrutiny could significantly impact the company’s development timeline and commercial prospects.
CID: 1488